menu
    • menu
    [{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Syneos Health","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGB Biopharma \/ Syneos Health","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Syneos Health"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Hammersmith Medicines Research | Innovate UK | Cambridge Regulatory Services | Phases Clinical Research | SGS Life Sciences | Viapath | Analytical Services International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGB Biopharma \/ Hammersmith Medicines Research | Innovate UK | Cambridge Regulatory Services | Phases Clinical Research | SGS Life Sciences | Viapath | Analytical Services International","highestDevelopmentStatusID":"6","companyTruncated":"MGB Biopharma \/ Hammersmith Medicines Research | Innovate UK | Cambridge Regulatory Services | Phases Clinical Research | SGS Life Sciences | Viapath | Analytical Services International"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGB Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"MGB Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Mgb-BP-3","moa":"DNA","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"MGB Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MGB Biopharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"MGB Biopharma \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by MGB Biopharma

    Menu

    MGB Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MGB Biopharma Announces End-of-Phase 2 Meeting with FDA for MGB-BP-3 as a Treatment for Clostridioides Diffici...

                            Details : Design and endpoints of two prospective Phase 3 studies were approved by the US FDA. The Phase 3 studies will include superiority of MGB-BP-3 against vancomycin in the critical measure of sustained clinical response as one of their endpoints.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 27, 2021

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MGB Biopharma Announces Successful Outcome From Phase II Clinical Study with MGB-BP-3

                            Details : The study confirms that MGB-BP-3, an antibacterial, has the potential to become the new gold standard, first-line treatment for CDI.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 19, 2020

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study to Assess Safety, Tolerability and Efficacy of Incremental Doses of MGB-BP-3 in Patients With CDAD

                            Details : Mgb-BP-3 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Clostridium Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 31, 2019

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Syneos Health

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            MGB Biopharma

                            United Kingdom arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase I

                            Sponsor : Hammersmith Medicines Research | Innovate UK | Cambridge Regulatory Services | Phases Clinical Research | SGS Life Sciences | Viapath | Analytical Services International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety, Blood Levels and Effects of MGB-BP-3

                            Details : Mgb-BP-3 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 10, 2015

                            Lead Product(s) : Mgb-BP-3

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase I

                            Sponsor : Hammersmith Medicines Research | Innovate UK | Cambridge Regulatory Services | Phases Clinical Research | SGS Life Sciences | Viapath | Analytical Services International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth